Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Efficacy and Safety of Ivarmacitinib in Active Ankylosing Spondylitis
NCT04481139Phase 3Completed
- Sponsor
- Hengrui
- Start
- Oct 2020
- Primary completion
- Nov 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of ivarmacitinib in ankylosing spondylitis (AS) (4 arms), sponsored by Hengrui. Primary endpoint: Assessment of SpondyloArthritis international Society 20 response at 12 weeks. Started Oct 2020; status: completed.
02
Drugs
ivarmacitinib
03
Conditions
ankylosing spondylitis (AS)
Beyond the preview
Go deeper on NCT04481139.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04481139.